Addex Therapeutics Secures €4M Eurostars Grant for mGlu2 NAM Program in Neurocognitive Disorder
Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has led a consortium which has been